Kontrol Technologies Corp (OTCQB:KNRLF, NEO:KNR). announced that it is shipping BioCloud units to distributors in Qatar and the Czech Republic as it continues to expand its technology footprint.
“The growing movement to employ air quality monitoring and early detection systems in buildings positions BioCloud well for growing adoption,” said Kontrol CEO Paul Ghezzi in a statement.
“Supported by an expanding global brand awareness and recognition of BioCloud as an innovative safe space solution, we expect to continue deployment of our technology to existing and new customers throughout the coming year.”
The company said the final phase of testing is anticipated to be completed in January or February 2022, subject to timelines that are not in its control. BioCloud is not a medical device and testing is being conducted at the request of various government agencies.
Following additional performance testing at the University of Western Ontario, the company said it will publish the results during the week of January 10, 2022, with a live laboratory video demonstrating the real-time response of the BioCloud analyzer with the dormant SARS-CoV-2 virus.
The additional testing was performed in conjunction with new interface features which were designed to be utilized and shared by researchers and applicable customers to validate the presence of the SARS-CoV-2 virus, and the level of detection response to better determine the safety of an area and effectiveness of current site safety protocols.
Shares of Kontrol jumped around 8% in afternoon trading at C$2.16 in Canada.
Contact the author: patrick@proactiveinvestors.com
Follow him on Twitter @PatrickMGraham